Atropine is a tertiary amine anticholinergic drug derived from the plant Atropa belladonna. Its primary mechanism of action in anesthesia revolves around competitive inhibition of acetylcholine at muscarinic receptors, leading to parasympathetic inhibition. Atropine’s parasympatholytic effects allow for sympathetic stimulation to predominate, making it useful in managing cardiac output, reducing salivary and respiratory secretions, and treating vagal-induced bradycardia. These properties make atropine a versatile drug in anesthesia, particularly in emergency or premedication settings.
Reduction of Salivary and Respiratory Secretions
Atropine is commonly used in anesthesia for its antisialagogue properties, where it reduces salivary and bronchial secretions to maintain a clear airway during surgical procedures. This effect is crucial during intubation and surgeries involving the upper airway or respiratory tract, where excess secretions can obstruct the airway and complicate airway management. Though glycopyrrolate is often preferred for its more potent antisialagogue effect and lack of central nervous system (CNS) penetration, atropine is still effective in situations where secretions need to be managed rapidly.
Prevention and Treatment of Bradycardia
Atropine is particularly useful in the prevention and treatment of bradycardia during anesthesia. Vagal stimulation, such as during intubation or surgical manipulation, can lead to vagal-induced bradycardia, a condition where the heart rate drops dangerously low. By blocking M2 muscarinic receptors in the heart’s sinoatrial (SA) node, atropine increases heart rate by reducing parasympathetic input. This action makes atropine the first-line therapy for treating symptomatic bradycardia during anesthesia, particularly in emergency situations where rapid correction is required.
Atropine is often used as part of rapid sequence intubation (RSI) pretreatment to prevent bradycardia, especially in pediatric patients who have a stronger vagal response. In these cases, atropine is administered 3 to 5 minutes before intubation to ensure that the heart rate remains stable during the procedure. Although this practice is less common in adults, it is still used in situations where repeat dosing of succinylcholine or other medications may trigger bradycardia.
Use in Reversing Neuromuscular Blockade
Atropine also plays an essential role in anesthesia during the reversal of neuromuscular blockade. Muscle relaxants, such as rocuronium or vecuronium, are used during surgery to facilitate intubation and maintain muscle paralysis. To reverse their effects postoperatively, cholinesterase inhibitors like neostigmine are administered to increase acetylcholine levels at the neuromuscular junction, allowing the muscles to regain function. However, increased acetylcholine also affects muscarinic receptors, which can cause bradycardia and excessive secretions. Atropine is co-administered to counteract these muscarinic effects, preventing bradycardia and allowing for a smooth recovery from anesthesia.
| Situation | How atropine is used |
|---|---|
| Pretreatment for rapid sequence intubation | Given 3 to 5 minutes before intubation so the heart rate stays stable through the procedure — most often in pediatric patients, whose vagal response is stronger |
| Repeat succinylcholine dosing in adults | Less common than in children, but still used where repeat dosing of succinylcholine or other medications may trigger bradycardia |
| Reversal of neuromuscular blockade | Co-administered with neostigmine to counteract the muscarinic effects of the rising acetylcholine — bradycardia and excessive secretions |
| Unstable patient, life-threatening bradycardia, or organophosphate poisoning | Administer regardless of potential contraindications |
